AUTHOR=Yang Guan-Jun , Liu Yan-Jun , Ding Li-Jian , Tao Fan , Zhu Ming-Hui , Shi Zhen-Yuan , Wen Juan-Ming , Niu Meng-Yao , Li Xiang , Xu Zhan-Song , Qin Wan-Jia , Fei Chen-Jie , Chen Jiong TITLE=A state-of-the-art review on LSD1 and its inhibitors in breast cancer: Molecular mechanisms and therapeutic significance JOURNAL=Frontiers in Pharmacology VOLUME=13 YEAR=2022 URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.989575 DOI=10.3389/fphar.2022.989575 ISSN=1663-9812 ABSTRACT=
Breast cancer (BC) is a kind of malignant cancer in women, and it has become the most diagnosed cancer worldwide since 2020. Histone methylation is a common biological epigenetic modification mediating varieties of physiological and pathological processes. Lysine-specific demethylase 1 (LSD1), a first identified histone demethylase, mediates the removal of methyl groups from histones H3K4me1/2 and H3K9me1/2 and plays a crucial role in varieties of cancer progression. It is also specifically amplified in breast cancer and contributes to BC tumorigenesis and drug resistance